Global investment firm BC Investments (Bain Capital) is likely set to sell up to 2% of pharmaceutical company Emcure Pharmaceuticals Ltd's total equity through a block deal, with an indicative floor price of ₹1,296.51 per share.

The price represents a discount of approximately 7% to Emcure Pharma’s closing price of ₹1,394.10 on the NSE on November 17, 2025. The block deal size is estimated at up to ₹493 crore.

Also Read: Emcure Pharma shares decline equity worth ₹574 crore changes hands in block deals

Shares sold through this transaction will have a 90-day lock-in period for further sale. BC Asia held a 6.3% stake in Emcure Pharmaceuticals at the end of Q2 2025.

Second Quarter Results

Emcure Pharmaceuticals reported a 25.1% year-on-year rise in consolidated net profit to ₹243

See Full Page